Arcturus Therapeutics, Inc. (ADHD) Therapeutics to Host Key Opinion Leader Call

0
122

Arcturus Therapeutics to Host Key Opinion Leader Call on Advances in Delivery of Nucleic Acid Medicines on Tuesday, November 7

Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it will host a live R&D webcast focused on the “Advances in Delivery of Nucleic Acid Medicines” on Tuesday, November 7 at 10:00 a.m. ET/ 7:00 a.m. PT.

The featured speakers on the webcast will be Pad Chivukula, Ph.D., Arcturus’s Chief Scientific Officer and Chief Operating Officer who has over 15 years of experience in nucleic acid delivery and therapeutic drug development; and Drew Weismann, M.D., Ph.D. who has co-discovered the ability of modified nucleosides in RNA to suppress activation of innate immune sensors and increase the translation of mRNA containing certain modified nucleosides.  Dr. Weismann continues to develop nucleoside modified mRNA as a new approach to therapeutic protein replacement.

“We are excited to share the innovative progress we’ve made in developing Arcturus’s technologies,” said Pad Chivukula, Ph.D., CSO and COO of Arcturus Therapeutics. “We are developing the next wave of nucleic acid chemistry and delivery technologies that have the potential to improve the quality of life for patients.”

Arcturus’s Key Opinion Leader Call will cover:

  • The history and advantages of non-immunogenic mRNA and its application into vaccine research by Drew Weismann, M.D., Ph.D.
  • Arcturus’s mRNA therapeutic platform technologies by Pad Chivukula, Ph.D., including:
    o Protein replacement
    o Gene editing

“The combination of nucleoside modified mRNA with Arcturus’s LUNAR™ complexing and delivery technology has the potential to treat a wide variety of illnesses and disorders,” said Dr. Weismann, Professor of Medicine at the Perelman School of Medicine, University of Pennsylvania.

Drew Weissman, M.D., Ph.D. is a professor of Medicine at the Perelman School of Medicine, University of Pennsylvania. He received his graduate degrees from Boston University School of Medicine.  Dr. Weissman co-discovered the ability of modified nucleosides in RNA to suppress activation of innate immune sensors and increase the translation of mRNA containing certain modified nucleosides. He continues to develop nucleoside modified mRNA as a new approach to deliver therapeutic proteins.  Dr. Weissman also develops methods to optimize vaccine efficacy by altering both the immunogen and the delivery system.  Dr. Weissman’s laboratory focuses on the study of RNA and innate immune system biology and the application of these findings to vaccine research, protein therapeutics, and gene therapy. His laboratory is currently developing new vaccine platforms, therapeutic proteins, and gene editing systems using nucleoside modified RNAs. He is also an Attending physician at the Philadelphia Veterans Administration Medical Center, a member of The American Association of Immunologists, and a member of the American Federation for Clinical Research.

Key Opinion Leader Call Details

Date:  Tuesday, November 7, 10:00 a.m. ET / 7:00 a.m. PT
Domestic: 888-245-0988
International: 719-325-4770
Conference ID: 3212426
Webcast with Slides: http://public.viavid.com/index.php?id=126992

About Arcturus Therapeutics, Inc. 
Founded in 2013 and based in San Diego, Arcturus Therapeutics, Inc. is an RNA medicines company with enabling technologies – UNA Oligomer chemistry and LUNAR™ lipid-mediated delivery.  Arcturus’s versatile RNA therapeutics platforms can be applied toward multiple types of RNA medicines including small interfering RNA, messenger RNA, antisense RNA, microRNA and gene editing therapeutics.  The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology including UNA Oligomers, which are covered by its patent portfolio (120 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries).  Arcturus’s proprietary UNA technology can be used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. The company’s commitment to the development of novel RNA therapeutics has led to partnerships with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, and Cystic Fibrosis Foundation Therapeutics Inc. For more information, visit www.ArcturusRx.com, the content of which is not incorporated herein by reference.

On September 27, 2017, Arcturus and Alcobra Ltd. (Alcobra) (ADHD) entered into an agreement and plan of merger and reorganization pursuant to which a wholly-owned subsidiary of Alcobra will merge with and into Arcturus, with Arcturus becoming a wholly owned subsidiary of Alcobra and the surviving corporation of the merger, and the holders of Arcturus outstanding capital stock immediately prior to the merger will receive ordinary shares representing approximately 60% of the outstanding shares of Alcobra. Upon consummation of the transaction, Alcobra’s name will be changed to Arcturus Therapeutics, Ltd., and Alcobra will change its ticker symbol to ARCT on NASDAQ.

LEAVE A REPLY

Please enter your name here
Please enter your comment!